Tyra Biosciences reported initial Phase 2 SURF302 results for dabogratinib in bladder cancer, marking an early clinical update for the drug candidate. The data add to the company’s ongoing push in NMIBC and broader bladder cancer development.
published
Tyra Biosciences reported initial Phase 2 SURF302 results for dabogratinib in bladder cancer, marking an early clinical update for the drug candidate. The data add to the company’s ongoing push in NMIBC and broader bladder cancer development.
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.